In Greek mythology, Telephus was a son of Heracles who received a wound in battle that would not heal until he returned to the Greek warrior, Achilles, who had inflicted the injury. He was healed by the very spear that had pierced him.
Real life is decidedly more complicated, but the fable is an apt metaphor for Telephus Medical LLC, which is developing a first-in-class humanized monoclonal antibody to prevent Staphylococcus reinfection and osteomyelitis in patients following total hip or knee replacement surgery. The company's technology is designed to prevent the early events that drive the formation of antibiotic-resistant biofilm infections on implanted medical devices, which today require additional, revision surgery.
Bacterial surface attachment is divided into three phases, explained Mark Benedyk, president and CEO of San Diego-based Telephus. They include primary reversible adhesion, secondary and irreversible adhesion and biofilm